Building on ALS results, Amylyx raises $30M ahead of Alzheimer’s readout
Also in ALS news: QurAlis obtains rights to Lilly compounds
Roughly six months after a placebo-controlled study showed that Amylyx’s lead product slowed disease progression in patients with ALS, the company has closed a $30 million series B round that will allow it to move forward with a clinical plan that also includes Alzheimer’s disease.
Existing investor Morningside Ventures led the round. Amylyx Pharmaceuticals Inc. CFO Jeffrey Trigilio told BioCentury more than 15 other investors,